Pricing Log in Create free account

AN2 Therapeutics, Inc. (ANTX) vs MacroGenics, Inc. (MGNX)

AN2 Therapeutics, Inc. and MacroGenics, Inc. are both Biotechnology companies. AN2 Therapeutics, Inc. and MacroGenics, Inc. are of similar size ($150.9M and $148.4M). AN2 Therapeutics, Inc. has the higher net margin (0.00% vs −8.70%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, AN2 Therapeutics, Inc. leads on 8 and MacroGenics, Inc. on 4.

Valuation

Metric ANTX MGNX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.88 9.40
P/B 2.36 3.46 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.61 0.66
EV/Sales n/m (0.11) 9.02
Earnings yield (26.75%) (9.44%) (32.88%)
Free cash flow yield (17.14%) (44.23%) (23.13%)

Profitability

Metric ANTX MGNX Biotechnology median
Gross margin 0.00% 85.23% 68.51%
Operating margin 0.00% (20.45%) 0.00%
Net margin 0.00% (8.70%) 0.00%
Free cash flow margin 0.00% (39.08%) 0.00%
Return on equity (50.12%) (32.61%) (51.96%)
Return on assets (46.06%) (4.94%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANTX MGNX Biotechnology median
Revenue growth (TTM) — 1.32% 6.76%
EPS growth (last fiscal year) 32.56% (10.28%) 29.88%
Revenue growth, 5-year CAGR — 7.35% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANTX MGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.32 2.96 4.97
Net debt to EBITDA 1.48 2.82 1.01

Dividend

Metric ANTX MGNX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANTX MGNX Biotechnology median
Market cap 150.94m 148.42m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack